EFFECTIVENESS OF TREATING GENETIC DISEASES BY GENE THERAPY

Authors

  • Olloqulova Khosiyat Kuvondik qizi, Sharipova Farida Salimjanovna Termez branch of Tashkent State Medical University image/svg+xml Author

Keywords:

gene therapy, genetic disorders, gene editing, CRISPR-Cas9, AAV vectors, lentiviral vectors, base editing, prime editing, gene delivery, monogenic disorders, spinal muscular atrophy, hemophilia, beta-thalassemia, sickle cell disease, hereditary retinal disorders.

Abstract

This article analyzes the effectiveness of gene therapy in treating genetic diseases, its main molecular mechanisms, and modern technologies. Key therapeutic approaches such as gene addition, gene function restoration, gene expression silencing, and targeted genome editing are covered. The potential of modern gene delivery and gene editing technologies, such as adeno-associated virus (AAV), lentiviral vectors, CRISPR-Cas9, base editing, prime editing, and lipid nanoparticles, is also considered. The results of modern research on the clinical efficacy of gene therapy in spinal muscular atrophy, hemophilia, hereditary retinal diseases, sickle cell disease, and beta-thalassemia are analyzed. Studies show that gene therapy can improve motor function, reduce bleeding, improve vision, reduce vaso-occlusive attacks, and achieve transfusion independence in some monogenic diseases. However, issues such as immunological reactions, off-target effects, vector limitations, long-term safety, high treatment costs, and proper patient selection for therapy were also discussed. In general, gene therapy is a promising treatment method that targets the molecular causes of genetic diseases, and its clinical effectiveness depends on the type of disease, the time of initiation of treatment, the characteristics of the genetic mutation, and the technology used.

References

1.Naldini L. Gene therapy returns to center stage. Nature. 2015;526(7573):351–360.

2.High KA, Roncarolo MG. Gene therapy. New England Journal of Medicine. 2019;381(5):455–464.

3.Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy is coming of age. Science. 2018;359(6372):eaan4672.

4.Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms in the gene therapy landscape. Signal Transduction and Targeted Therapy. 2021;6:53.

5.Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nature Reviews Drug Discovery. 2019;18(5):358–378.

6.Mendell JR, Al-Zaidy S, Shell R, et al. A single-dose gene replacement therapy for spinal muscular atrophy. New England Journal of Medicine. 2017;377(18):1713–1722.

7.Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2: the STR1VE trial. Lancet Neurology. 2021;20(4):284–293.

8.Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec: SPR1NT trial for infants with type 1 spinal muscular atrophy who have no symptoms and have two copies of SMN2. Nature Medicine. 2022;28:1381–1389.

9.Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk of spinal muscular atrophy: the SPR1NT trial. Nature Medicine. 2022;28:1390–1397.

10.Pipe SW, Leebeek FWG. New treatments for hemophilia: a paradigm shift. Hematology. 2019;2019(1):26–34.

11.Pipe SW et al. Gene therapy with Etranacogene Dezaparvovec for Hemophilia B. New England Journal of Medicine. 2023;388:706–718.

12.Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. New England Journal of Medicine. 2022;386:1013–1025.

13.Mahlangu J, Kaczmarek R, von Drygalski A, et al. Hemophilia is a valoctocogen for a roxaparvovec three-year results of gene therapy. Blood Advances. 2024.

14.Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec in patients with RPE65-mediated hereditary retinal dystrophy. Lancet. 2017;390(10097):849–860.

15.Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine. 2021;384:252–260.

16.Frangoul H, Ho TW, Corbacioglu S, et al. Exagamglogene autotemcel for severe sickle cell disease. New England Journal of Medicine. 2024;390(18):1649–1662.

17.Thompson AA, Walters MC, Kvyatkovski J, et al. Gene therapy in patients with transfusional β-thalassemia. New England Journal of Medicine. 2018;378:1479–1493.

18.Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533:420–424.

19.Gaudelli NM, Komor AC, Rees HA, et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature. 2017;551:464–471.

20.Anzalone AV, Randolph PB, Davis JR, et al. Genome-wide search and replacement without double-stranded breaks or donor DNA. Nature. 2019;576:149–157.

21.Doudna JA, Charpentier E. A new frontier in genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.

22.Pickar-Oliver A, Gersbach CA. The next generation of CRISPR-Cas technologies and applications. Nature Reviews Molecular Cell Biology. 2019;20:490–507.

23.Setten RL, Rossi JJ, Han SP. Current status and future directions of RNAi-based therapy. Nature Reviews Drug Discovery. 2019;18:421–446.

24.Mingozzi F, High KA. Overcoming the challenges of AAV-based gene therapy: immune responses and toxicity. Molecular Therapy. 2013;21:1–8.

25.Fu Y, Foden JA, Khayter C, et al. High-frequency targeted mutagenesis in human cells induced by CRISPR-Cas nucleases. Nature Biotechnology. 2013;31:822–826.

26.World Health Organization. Human Genome Editing: Recommendations. Geneva: World Health Organization; 2021.

Downloads

Published

2026-09-11